Analysts have revised Y-mAbs Therapeutics, Inc.'s forecasts, predicting lower revenues and increased losses per share for 2025. The consensus price target fell by 12%, indicating a potential impact on the company's valuation.
Read MoreDid you find this insightful?
Bad
Just Okay
Amazing